5月20日早间,三生制药公告与辉瑞就PD-1/VEGF双特异性抗体SSGJ-707订立协议,辉瑞将获得该产品在全球(不包括中国内地)的权益。本次交易价格为12.5亿美元的首付款及最多48亿美元的潜在里程碑付款,并收取两位数百分比的特许权使用费。此外,辉瑞将于协议生效日认购三生制药价值1亿美元的普通股股份。三生制药在香港上市,为恒生医药ETF(159892)持仓股。2024年财报显示,三生制药实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.